Navigation Links
PDL BioPharma Provides Fourth Quarter 2011 Revenue Guidance of $72 Million
Date:12/19/2011

INCLINE VILLAGE, Nev., Dec. 19, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2011 of approximately $72 million, as compared with actual results of $76 million for the fourth quarter of 2010, a five percent decrease. Total anticipated revenue for the year ended December 31, 2011 is $361 million as compared with actual results of $345 million for the year ended December 31, 2010, a five percent increase.

(Logo:  http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

The forecasted fourth quarter 2011 revenue decline is primarily driven by reduced royalties from third quarter 2011 sales of Avastin® and Herceptin® partially offset by increased royalties from third quarter 2011 sales of Lucentis® and Tysabri®. Sales of Avastin, Herceptin, Lucentis, and Xolair® (the Genentech Products) are subject to a tiered royalty rate for product that is made or sold in the United States and a flat royalty rate of three percent for product that is manufactured and sold outside of the United States. The net sales thresholds and the applicable royalty rates for the Genentech Products are outlined below:Genentech Products Made or Sold in US

Royalty RateNet sales up to $1.5 billion

3.0%Net sales between $1.5 billion and $2.5 billion

2.5%Net sales between $2.5 billion and $4.0 billion

2.0%Net sales exceeding $4.0 billion

1.0% 

 Genentech Products Made and Sold ex-US

 Net sales

3.0%The revenue guidance for the fourth quarter is net of the estimated payment due under our February 2011 settlement agreement with Novartis, which is based on a portion of the royalties that the Company receives for Lucentis sales made
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Perceptive Informatics Completes Over 500 System Integrations as the Biopharma Industry Continues to Adopt Seamless eClinical Solutions
2. Keryx Biopharmaceuticals Announces Phase 2 Data for KRX-0401 (Perifosine) in Hodgkins Lymphoma Presented at ASH Meeting
3. Inspiration Biopharmaceuticals Presents Key Scientific Data from its Two Lead Hemophilia Development Programs at the 53rd Annual Meeting of the American Society of Hematology (ASH)
4. NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors
5. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
6. PAREXEL Strengthens Late Phase and Observational Research Capabilities With Expert Team to Help Biopharma Meet Commercialization Goals
7. Genesis Biopharmas Scientific and Medical Advisory Board Welcomes Dr. Steven A. Rosenberg, Chief of the Surgery Branch at the NCI
8. PDL BioPharma Inc. Announces Exchange Offer for Its 2.875% Convertible Senior Notes Due February 15, 2015
9. Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
10. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
11. PDL BioPharma Announces Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... TWINSBURG, Ohio , Aug. 31, 2015 /PRNewswire/ ... and applications, has acquired MACTek Corporation, a leading ... part of Pepperl+Fuchs, strategy to further extend its ... the WirelessHART market.    "We are ... to our existing portfolio," said Jim Bolin ...
(Date:8/31/2015)... 2015 Thousands of people will peacefully demonstrate ... opioid addiction epidemic at dozens of rallies across the ... the United States has experienced ... opioids and heroin, yet the President has never once ... letter to President Obama , rally organizers compared ...
(Date:8/31/2015)... , August 31, 2015 ... the global cardiovascular monitoring and diagnostic devices market ... predicted to reach a value of approximately US$7.0 ... 9.7% between 2013 and 2019. The title of ... Market (ECG, Holter Monitors, Event Monitors, Cardiovascular Diagnostic ...
Breaking Medicine Technology:Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5
(Date:8/31/2015)... ... ... Dr. Stewart Shofner of Shofner Vision Center explains what causes lazy ... eye examination can diagnose amblyopia. According to the National Eye Institute (NEI), ... to 3 out of every 100 children. , Dr. Shofner adds, “unless amblyopia ...
(Date:8/31/2015)... ... August 31, 2015 , ... Nine innovative healthcare companies (listed ... in Healthcare(SM) Awards Event , on October 21, 2015, in Long Beach. The ... organizations and individuals who are dramatically reducing the cost of quality healthcare. , ...
(Date:8/31/2015)... ... 2015 , ... Finnleo is pleased to announce another in a ... of extensive engineering and design of our newest sauna model, the Terrace combines high ... offered at a very attractive price-point. , Before outdoor saunas were a dream ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... and accessible primary care, is enhancing its existing presence in Tennessee with the ... The location is the company’s second in Knoxville, sixteenth in Tennessee, and 148th ...
(Date:8/31/2015)... New York (PRWEB) , ... August 31, 2015 , ... ... autumn, when play-offs and the World Series will dominate the sports world. Fans desire ... and eventually advance to the final series. For children, especially those who are too ...
Breaking Medicine News(10 mins):Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8Health News:Say “Hello” to the Brand New Finnleo Terrace Outdoor Saunas 2Health News:State-of-the-Art Urgent Care Facility Opening in Knoxville 2Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2
... illusion; ridiculous, says former star major league pitcher , FRIDAY, ... the pitcher,s hand. In less than a second, it curves ... , The curveball, when thrown correctly, is one of baseball,s ... and not so great have sworn that the ball seems ...
... FRANCISCO, Calif., Oct. 30 Anesiva, Inc. (Nasdaq: ANSV ... Stockholders will be held on December 3, 2009 at 9:00 ... Francisco, California. Stockholders of record at the close of ... at the 2009 Annual Meeting of Stockholders. The definitive ...
... (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, ... Tablets, at a major psychiatric medical meeting today. ... the change from baseline on the oppositional subscale of ... in patients ages 6 to 12 with a primary ...
... around right after procedure cuts conception rate, study found ... lie flat for 15 minutes after being artificially inseminated ... suggests. , "Allowing women treated for subfertility with IUI ... a 50 percent higher chance at conceiving," said Inge ...
... ... joined the crusade to better our environment by offering green printing services and eco-friendly ... information for the company,s custom labels offering. , ... Fort Scott, KS (PRWEB) October 30, 2009 --, , ...
... infants, studies show , FRIDAY, Oct. 30 (HealthDay ... who should get H1N1 swine flu and seasonal flu ... vaccination for moms-to-be and their babies. , Bigger, healthier ... top the findings, which are to be presented this ...
Cached Medicine News:Health News:Scientist Throws Curve Into Breaking-Ball Debate 2Health News:Scientist Throws Curve Into Breaking-Ball Debate 3Health News:Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 2Health News:Anesiva Announces Date for 2009 Annual Meeting of Stockholders to Vote on Proposed Merger 3Health News:INTUNIV demonstrated symptom reduction on oppositional subscale Conners' ADHD rating scale 2Health News:INTUNIV demonstrated symptom reduction on oppositional subscale Conners' ADHD rating scale 3Health News:Lying Still Raises Artificial Insemination Success 2Health News:Lying Still Raises Artificial Insemination Success 3Health News:My1Stop.com Launches New Custom Labels Solutions Making Pricing and Ordering Faster and Easier 2Health News:Flu Shot in Pregnancy Protects Baby 2Health News:Flu Shot in Pregnancy Protects Baby 3
Bipolar semi-floating pacing lead for temporary stimulation of the heart especially in emergency cases of bradycardial arrhythmias or for recording intracardiac ECGs....
The HT-PB is a implantable bipolar tined permanent pacing lead for stimulation of the ventricle....
... Flextend lead is a ... with an extendable/retractable active-fixation ... design offers various lead ... implantation in the atrium ...
The RU is a low profile implantable bipolar tined permanent pacing lead for stimulation of either the atrium (J model) or the ventricle (straight model)....
Medicine Products: